Sanofi reports on Phase-II PCSK9 trial

Share this article:

Sanofi reported positive results from the Phase-II trial it conducted in Japan of PCSK9 inhibitor alirocumab. The trial was designed to demonstrate reduction of LDL or bad cholesterol from baseline to week 12. At week 12, average LDL reduction was 55% at 50mg, 62% at 75mg, and 72% at 150mg. The placebo group saw an average LDL reduction of 3%.

Regeneron's chief scientific officer, George Yancopoulous, commented, “Not only was alirocumab shown, in this study, to significantly reduce LDL-C in this patent population, the results of this study also demonstrate the potential efficacy of alirocumab at a range of doses.”

Dosing differences could play a bigger role if drugs like alirocumab reach market. With other mid-to-late-stage trials having demonstrated their ability to lower cholesterol, questions surrounding the emergent PCSK9 class are now commercial not clinical, analysts said recently.
 

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.